author-photo

Sandhya Sapra

GlaxoSmithKline

5

Papers

4

Citations

Citation Trend

Filter By

Papers (4) Sort By

Journal Conference Others

Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis.

2021 Expert Review of Hematology
Show All
- Source
- Cite
- Save
Citations (0)
Landscape review of the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in oncology: Adoption and recent learnings.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
MM-200: A Qualitative Study of Patients’ Preferences for the Treatment of Relapsed or Refractory Multiple Myeloma (RRMM) in the United States, United Kingdom, France, and Germany

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) Effects on Patient-Reported Outcome (PRO) Measures in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

2020 Blood
Show All
- Source
- Cite
- Save
Citations (2)